keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/28540419/therapy-assessment-in-prostate-cancer-using-choline-and-psma-pet-ct
#1
REVIEW
Francesco Ceci, Ken Herrmann, Boris Hadaschik, Paolo Castellucci, Stefano Fanti
While PET with non-FDG tracers (mainly choline and Ga-PSMA) has commonly been used for restaging in men with biochemically recurrent prostate cancer, as well as for primary staging, it is only recently that a few preliminary studies have addressed the possible use of PET for monitoring the response to systemic therapy of metastatic disease, especially innovative treatments such as abiraterone and enzalutamide. This article aims to evaluate the role of PET imaging with different non-FDG radiotracers for assessment of therapy in advanced prostate cancer patients...
May 25, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28536833/development-of-standardized-image-interpretation-for-68ga-psma-pet-ct-to-detect-prostate-cancer-recurrent-lesions
#2
Stefano Fanti, Silvia Minozzi, Joshua James Morigi, Frederik Giesel, Francesco Ceci, Christian Uprimny, Michael S Hofman, Matthias Eiber, Sarah Schwarzenbock, Paolo Castellucci, Cristina Bellisario, Stéphane Chauvie, Fabrizio Bergesio, Louise Emmett, Uwe Haberkorn, Irene Virgolini, Markus Schwaiger, Rodney J Hicks, Bernd J Krause, Arturo Chiti
METHODS: After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence...
May 23, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28534214/repeatability-of-68-ga-dkfz11-psma-pet-scans-for-detecting-prostate-specific-membrane-antigen-positive-prostate-cancer
#3
Joseph R Osborne, Teja M Kalidindi, Blesida J Punzalan, Kishore Gangangari, Daniel E Spratt, Wolfgang A Weber, Steven M Larson, Naga Vara Kishore Pillarsetty
PURPOSE: We studied the effect of varying specific activity of [(68)Ga]DKFZ-PSMA11 ([(68)Ga]DP11) on repeated imaging of prostate-specific membrane antigen-positive (PSMA+) xenograft tumors. PROCEDURES: Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA-) bilateral flank tumors were assessed to study intra- and inter-day repeatability of [(68)Ga]DP11 imaging in mice administered [(68)Ga]DP11 or [(67)Ga]DP11 (as a dilution tracer) using imaging and biodistribution studies...
May 22, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28533936/synthesis-and-evaluation-of-64-cu-psma-617-targeted-for-prostate-specific-membrane-antigen-in-prostate-cancer
#4
Can Cui, Masayuki Hanyu, Akiko Hatori, Yiding Zhang, Lin Xie, Tomoya Ohya, Masami Fukada, Hisashi Suzuki, Kotaro Nagatsu, Cuiping Jiang, Rui Luo, Guoqiang Shao, Mingrong Zhang, Feng Wang
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 ((64)Cu), to evaluate the metabolism, biodistribution, and potential of [(64)Cu]PSMA-617 for PET imaging of prostate cancer. [(64)Cu]PSMA-617 was synthesized by heating PSMA-617 with [(64)Cu]CuCl2 in buffer solution at 90°C for 5 min. In vitro uptake was determined in two cell lines of prostate cancer. In vivo regional distributions were determined in normal and tumor-bearing mice. High radiolabeling efficiency of (64)Cu for PSMA-617 yielded [(64)Cu]PSMA-617 with >99% radiochemical purity...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28533806/second-salvage-high-dose-rate-brachytherapy-for-radiorecurrent-prostate-cancer
#5
Metha Maenhout, Marco van Vulpen, Marinus Moerland, Max Peters, Richard Meijer, Maurice van den Bosch, Paul Nguyen, Steven Frank, Jochem van der Voort van Zyp
PURPOSE: Salvage treatments for localized radiorecurrent prostate cancer can be performed safely when a focal and image guided approach is used. Due to the low toxicity, the opportunity exists to investigate a second salvage treatment when a second locally recurrent prostate cancer occurs. Here, we describe a second salvage treatment procedure of 4 patients. MATERIAL AND METHODS: Four patients with a pathologically proven second local recurrence were treated in an outpatient magnetic resonance imaging (MRI)-guided setting with a single fraction of 19 Gy focal high-dose-rate brachytherapy (HDR-BT)...
April 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28533654/psma-expression-in-multinodular-thyroid-neoplasm-on-simultaneous-ga-68-psma-pet-mri
#6
Amarnath Jena, Shuaib Zaidi, Vikas Kashyap, Abhishek Jha, Sangeeta Taneja
PSMA PET is increasingly being used in imaging of recurrent prostate carcinoma. A case with suspected recurrent Prostate carcinoma (PCa), raised PSA (Prostate specific antigen) and suspected spinal metastases was referred for whole body Ga-68-PSMA PET/MRI. The study revealed PSMA avid recurrent prostate mass and extensive osseous metastases. Abnormal PSMA uptake in the thyroid gland prompted USG-guided FNAC which revealed Hurthle cell neoplasm. Histopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533638/clinical-utility-of-gallium-68-psma-pet-ct-scan-for-prostate-cancer
#7
Kumaraswamy G Kallur, Prashanth G Ramachandra, Krishnappa Rajkumar, Shivakumar S Swamy, Indiresh Desai, Raghavendra M Rao, Shekhar Gowda Patil, P S Sridhar, Nagaraj Madhusudhan, Raghunath S Krishnappa, Veerendra Bhadrasetty, Hemantha M Kumara, S D Santhosh, Basavalingaiah S Ajaikumar
BACKGROUND: Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer. METHODS: In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533634/estimation-of-whole-body-radiation-exposure-to-nuclear-medicine-personnel-during-synthesis-of-177-lutetium-labeled-radiopharmaceuticals
#8
Geetanjali Arora, Rajesh Mishra, Praveen Kumar, Madhav Yadav, Sanjana Ballal, Chandrasekhar Bal, Nishikant Avinash Damle
PURPOSE OF THE STUDY: With rapid development in the field of nuclear medicine therapy, radiation safety of the personnel involved in synthesis of radiopharmaceuticals has become imperative. Few studies have been done on estimating the radiation exposure of personnel involved in the radio labeling of (177)Lu-compounds in western countries. However, data from the Indian subcontinent are limited. We have estimated whole body radiation exposure to the radiopharmacist involved in the labeling of: (177)Lu-DOTATATE, (177)Lu-PSMA-617, and (177)Lu-EDTMP...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28529650/diagnostic-accuracy-of-ga-68-hbed-cc-psma-ligand-pet-ct-before-salvage-lymph-node-dissection-for-recurrent-prostate-cancer
#9
Cordula A Jilg, Vanessa Drendel, H Christian Rischke, Teresa Beck, Werner Vach, Kathrin Schaal, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer
Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND). Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa...
2017: Theranostics
https://www.readbyqxmd.com/read/28525451/metastases-from-colorectal-cancer-avid-on-68ga-psma-pet-ct
#10
Lise Hangaard, Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Kirsten Bouchelouche
Ga-PSMA PET/CT is currently used for detection of prostate cancer including metastases, even at low prostate-specific antigen values. A grown number of reports have shown increased uptake of PSMA in neovessels of nonprostatic malignancies including lung cancer, and recently a case report has demonstrated increased PSMA uptake in colorectal adenocarcinoma. In this case report, we demonstrate increased Ga-PMSA uptake on PET/CT in metastases from previously treated colon adenocarcinoma, and it illustrates the importance of histology of suspicious lesions on Ga-PSMA PET/CT...
May 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28522741/impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#11
Thomas A Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L Greene, Matthew Cooperberg, Felix Feng, Albert Chang, Charles J Ryan, Eric J Small, Peter R Carroll
Purpose: The purpose of this prospective study was to estimate the effect of (68)Ga-prostate specific membrane antigen (PSMA)-11 PET on intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and post-imaging surveys were filled out by referring providers in patients with biochemical recurrence who were imaged using (68)Ga-PSMA-11 PET. Inclusion criteria for this study required a PSA doubling time of less than 12 months after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate)...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522740/initial-experience-with-volumetric-68-ga-psma-i-t-pet-ct-for-assessment-of-whole-body-tumor-burden-as-a-quantitative-imaging-biomarker-in-patients-with-prostate-cancer
#12
Sebastian Schmuck, Christoph A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether prostate specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) may be applied to provide PSMA-derived volumetric parameters for quantification of whole-body tumor burden. Methods: 101 patients who underwent a (68)Ga-PSMA I&T PET/CT because of increasing prostate specific antigen (PSA) levels after radical prostatectomy were included in this retrospective analysis...
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522737/why-targeting-psma-is-a-valuable-addition-in-the-management-of-castration-resistant-prostate-cancer-the-urologists-point-of-view
#13
Boris Hadaschik, Martin Boegemann
No abstract text is available yet for this article.
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28522176/re-diagnostic-accuracy-of-ga-68-hbed-cc-psma-ligand-pet-ct-before-salvage-lymph-node-dissection-for-recurrent-prostate-cancer
#14
Boris Hadaschik, Ken Herrmann
No abstract text is available yet for this article.
May 15, 2017: European Urology
https://www.readbyqxmd.com/read/28511221/-psma-radioguided-surgery-for-salvage-lymphadenectomy-in-recurrent-prostate-cancer
#15
Isabel Rauscher, Matthias Eiber, Tobias Maurer
Recently, the use of (111)In-labeled PSMA-I&T-based radioguided surgery ((111)In-PSMA(-)RGS) for salvage surgery using intraoperative ex-vivo γ-probe measurements has been described by our group as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). (111)In-PSMA-RGS allowed for the intraoperative identification of metastatic lesions with a sensitivity, specificity and accuracy of 92.3, 93.5 and 93.1%, respectively, compared to histopathology. (111)In-PSMA-RGS was able to detect 5 additional lymph node metastases in 3 out of 31 patients compared to (68)Ga-HBED-CC-PSMA PET...
April 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28511220/-significance-and-value-of-psma-ligands-in-prostate-cancer
#16
Claudia Gasch, Stefan Körber, Christophe Kremer, Matthias Eiber, Clemens Kratochwil, Uwe Haberkorn, Markus Hohenfellner, Boris Hadaschik, Frederik L Giesel
In recent years, PSMA-targeting PET tracers such as (68)Ga-PSMA-11 have shown promising results, thus contributing to a better management of prostate cancer patients. At the present time, (68)Ga-PSMA-11 is most frequently used for diagnostic evaluation in the setting of biochemical recurrence of prostate cancer. In this context, the (68)Ga-PSMA-11 PET/CT delivers superior detection rates compared to conventional imaging, especially for the detection of small, unsuspicious lesions or lesions in the presence of low PSA values...
April 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28508120/effects-of-arm-truncation-on-the-appearance-of-the-halo-artifact-in-68-ga-psma-11-hbed-cc-pet-mri
#17
Ali Afshar-Oromieh, Maya Wolf, Uwe Haberkorn, Marc Kachelrieß, Regula Gnirs, Klaus Kopka, Heinz-Peter Schlemmer, Martin T Freitag
PURPOSE: PSMA ligand imaging with hybrid PET/MRI scanners could be an integral part of the clinical routine in the future. However, the first study about this novel method revealed a severe photopenic artifact ("halo artifact") around the urinary bladder causing significantly reduced tumor visibility. The aim of this evaluation was to analyze the role of arm truncation on the appearance of the halo artifact in (68)Ga-PSMA-11 PET/MRI hypothesizing that this influences the appearance. METHODS: Twenty-seven consecutive patients were subjected to (68)Ga-PSMA-11 PET/CT (1 h p...
May 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28499607/evaluation-of-intensity-modulated-radiation-therapy-dose-painting-for-localized-prostate-cancer-using-68-ga-hbed-cc-psma-pet-ct-a-planning-study-based-on-histopathology-reference
#18
Constantinos Zamboglou, Ilias Sachpazidis, Khodor Koubar, Vanessa Drendel, Rolf Wiehle, Simon Kirste, Michael Mix, Florian Schiller, Panayiotis Mavroidis, Philipp T Meyer, Martin Werner, Anca L Grosu, Dimos Baltas
PURPOSE: To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of IMRT dose painting using (68)Ga-HBED-CC PSMA PET/CT for target delineation in prostate cancer (PCa). METHODS AND MATERIALS: 10 patients had PSMA PET/CT scans prior to prostatectomy. GTV-PET was generated on the basis of an intraprostatic SUVmax of 30%. Two IMRT plans were generated for each patient: Plan(77) which consisted of whole-prostate IMRT to 77Gy, and Plan(95) which consisted of whole-prostate IMRT to 77Gy and a simultaneous integrated boost to the GTV-PET up to 95Gy (35 fractions)...
May 9, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28497198/diagnostic-performance-of-68-ga-psma-11-hbed-cc-pet-ct-in-patients-with-recurrent-prostate-cancer-evaluation-in-1007-patients
#19
Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn
PURPOSE: Since the clinical introduction of (68)Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort. METHODS: We performed a retrospective analysis of 1007 consecutive patients who were scanned with (68)Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease...
May 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28490470/metal-artifact-reduction-of-ct-scans-to-improve-pet-ct
#20
Charlotte S van der Vos, Anne Ij Arens, Jim Hamill, Christian Hofmann, Vladimir Y Panin, Antoi Pw Meeuwis, Eric P Visser, Lioe-Fee de Geus-Oei
In recent years different metal artifact reduction (MAR) methods have been developed for computed tomography (CT). These methods have only recently been introduced for positron emission tomography/computed tomography (PET/CT) even though they could be beneficial for interpretation, segmentation and quantification of the PET/CT images. In this study, phantom and patient scans were analyzed visually and quantitatively to measure the effect on PET images of iterative metal artifact reduction (iMAR) of CT data...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"